OMNIPAQUE 70 Drug Patent Profile

When do Omnipaque 70 patents expire, and when can generic versions of Omnipaque 70 launch?

Omnipaque 70 is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in OMNIPAQUE 70 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.

Summary for OMNIPAQUE 70

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	25
Patent Applications:	3,836
DailyMed Link:	OMNIPAQUE 70 at DailyMed

Recent Clinical Trials for OMNIPAQUE 70

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Claire Bourgeois	Phase 4
Fédération des médecins résidents du Québec	Phase 4
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal	Phase 4

See all OMNIPAQUE 70 clinical trials

Pharmacology for OMNIPAQUE 70

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for OMNIPAQUE 70

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994		DISCN	No	No

Expired US Patents for OMNIPAQUE 70

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994	4,250,113
Ge Healthcare	OMNIPAQUE 70	iohexol	SOLUTION;URETHRAL	018956-007	Jun 1, 1994	4,396,597

International Patents for OMNIPAQUE 70

See the table below for patents covering OMNIPAQUE 70 around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	445971	FORFARANDE FOR FRAMSTELLNING AV INJICERBART RONTGENKONTRASTMEDEL SAMT EN LOSNING AV NEMNDA MEDEL
Ireland	48437	A PROCESS FOR THE PREPARATION OF A STERILE INJECTABLE PHYSIOLOGICALLY ACCEPTABLE SOLUTION OF AN X-RAY CONTRAST AGENT AND SOLUTIONS OF THE X-RAY CONTRAST AGENT AND A BUFFER
Finland	792101
France	2053037
Canada	935153	2,4,6-TRIIODOBENZOYL AMINES USED AS X-RAY CONTRAST AGENTS
Japan	S5321137	XXRAY CONTRAST MEDIUM
Norway	129093

OMNIPAQUE 70 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for OMNIPAQUE (Iohexol)

Introduction to OMNIPAQUE (Iohexol)

OMNIPAQUE, also known as iohexol, is a non-ionic, water-soluble contrast agent used in radiographic studies. It is available in various iodine concentrations, including 140, 180, 240, 300, and 350 mgI/mL, but this article will focus on the market dynamics and financial trajectory of OMNIPAQUE, particularly the 70 mgI/mL concentration, although specific financial data for this exact concentration might be less detailed.

Global Iohexol Market Overview

The global iohexol market, which includes OMNIPAQUE, was valued at around USD 1.5 billion in 2022. This market is projected to grow at a compound annual growth rate (CAGR) due to increasing demand for diagnostic imaging procedures and the expanding prevalence of diseases that require such diagnostics[1].

Market Segmentation

By Product Type

The iohexol market is segmented based on product type, including different concentrations of iohexol. While the 70 mgI/mL concentration is not as commonly highlighted as the higher concentrations, it still plays a crucial role in specific diagnostic procedures. The market attractiveness and BPS (basis point share) analysis by product type indicate that each concentration has its niche market and application areas[1].

By Region

Geographically, the iohexol market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Each region has its own market dynamics, driven by factors such as healthcare infrastructure, regulatory environments, and patient demographics. For instance, North America and Europe are significant markets due to their advanced healthcare systems and high demand for diagnostic imaging[1].

Competitive Landscape

The competitive landscape of the iohexol market is characterized by several key players. Companies like GE Healthcare, which markets OMNIPAQUE, compete with other pharmaceutical and diagnostic imaging companies. The market value and volume share by company indicate a competitive but consolidated market, with a few major players dominating the scene[1].

Growth Drivers

Increasing Demand for Diagnostic Imaging

The growing need for diagnostic imaging due to an increase in chronic diseases and the aging population is a significant driver for the iohexol market. As more people undergo medical imaging procedures, the demand for contrast agents like iohexol increases.

Technological Advancements

Advancements in imaging technologies, such as CT scans and MRI, have improved the accuracy and efficiency of diagnostic procedures, further boosting the demand for contrast agents.

Regulatory Approvals

Regulatory approvals and compliance play a crucial role in the market growth. For example, OMNIPAQUE has been approved by regulatory bodies like the FDA for various indications, which helps in its widespread adoption[4].

Financial Trajectory

Revenue and Market Value

The global iohexol market revenue is expected to grow significantly over the forecast period. While specific financial data for the 70 mgI/mL concentration of OMNIPAQUE might not be readily available, the overall market trend indicates a positive financial trajectory. The revenue by manufacturers and revenue share analysis provides insights into the financial performance of key players in the market[1].

Pricing Strategies

The pricing of iohexol products, including OMNIPAQUE, varies based on concentration and region. The pricing strategy is influenced by factors such as production costs, market demand, and competitive landscape. Higher concentrations like 300 and 350 mgI/mL tend to be more expensive due to their broader application in complex diagnostic procedures[1].

Mergers and Acquisitions

The pharmaceutical industry, including the iohexol market, has seen several mergers and acquisitions that impact market dynamics. For instance, the acquisition and divestment activities by companies like Daiichi Sankyo, although not directly related to iohexol, illustrate the broader industry trends that can influence the competitive landscape and financial performance of companies involved in the iohexol market[2][3].

Regional Market Analysis

North America

North America is a significant market for iohexol due to its advanced healthcare infrastructure and high demand for diagnostic imaging. The historical market value and volume forecasts indicate steady growth in this region[1].

Europe

Europe also represents a substantial market, driven by similar factors as North America. The market attractiveness and BPS analysis by product type in Europe highlight the region's importance in the global iohexol market[1].

Asia-Pacific

The Asia-Pacific region is growing rapidly due to increasing healthcare spending and a rising demand for diagnostic imaging. This region is expected to contribute significantly to the future growth of the iohexol market[1].

Trends in the Global Iohexol Market

Technological Innovations

Continuous technological innovations in imaging technologies and contrast agents are driving the market forward. These innovations improve the safety, efficacy, and convenience of diagnostic procedures.

Regulatory Changes

Regulatory changes and updates can significantly impact the market. For example, any changes in FDA regulations or approvals can affect the market dynamics and financial performance of iohexol products.

Market Expansion

Companies are expanding their market presence through strategic partnerships and geographic expansion. This trend is expected to continue, driving growth in the iohexol market.

Challenges and Barriers

Regulatory Hurdles

Navigating regulatory environments can be challenging. Companies must comply with various regulations across different regions, which can be time-consuming and costly.

Competition

The iohexol market is competitive, with several key players. This competition can lead to pricing pressures and make it challenging for new entrants to gain market share.

Economic Factors

Economic factors such as currency fluctuations and changes in healthcare policies can impact the market. For instance, a strong appreciation of the yen, as experienced by Daiichi Sankyo, can negatively impact sales[3].

Key Takeaways

• The global iohexol market, including OMNIPAQUE, is growing due to increasing demand for diagnostic imaging.
• The market is segmented by product type and region, with North America and Europe being significant markets.
• Technological advancements and regulatory approvals are key drivers of market growth.
• The financial trajectory of the market is positive, with expected growth in revenue and market value.
• Mergers and acquisitions, as well as regional market dynamics, play crucial roles in shaping the market.

FAQs

What is OMNIPAQUE (iohexol) used for?

OMNIPAQUE (iohexol) is a contrast agent used in radiographic studies to enhance the visibility of internal body structures during diagnostic imaging procedures.

What are the different concentrations of OMNIPAQUE available?

OMNIPAQUE is available in various iodine concentrations, including 140, 180, 240, 300, and 350 mgI/mL.

What drives the growth of the iohexol market?

The growth of the iohexol market is driven by increasing demand for diagnostic imaging, technological advancements, and regulatory approvals.

Who are the key players in the iohexol market?

Key players in the iohexol market include companies like GE Healthcare, which markets OMNIPAQUE, along with other pharmaceutical and diagnostic imaging companies.

How does the competitive landscape affect the iohexol market?

The competitive landscape is characterized by a few major players dominating the market, leading to competitive pricing and market share dynamics.

Sources

1. KDMI Report: Iohexol Market Size, Share, Growth, Trends And Future Outlook 2032.
2. Daiichi Sankyo Group Value Report 2018: Financial and operational details of Daiichi Sankyo.
3. Daiichi Sankyo Co., Ltd. Annual Report 2010: Market trends and financial performance of Daiichi Sankyo.
4. FDA Label: OMNIPAQUE (iohexol) Injection label details.